{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5b0fd1107b67904376d520f7/636248b938760d001148a226?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Next, GlaxoSmithKline, and China with Alan Green","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5b0fd1107b67904376d520f7/1528450062858-bed092fdeb27e812728e9e7b55a3d7a5.jpeg?height=200","description":"<p>Alan Green joins the Podcast as we explore UK equities and key macro themes driving markets this week.&nbsp;</p><p><br></p><p>We discuss:</p><p><br></p><ul><li><strong>Next (LON:NXT)</strong></li><li><strong>GlaxoSmithKline (LON:GSK)</strong></li><li><strong>Sovereign Metals (LON:SVML)</strong></li><li><strong>ECR Minerals (LON:ECR)</strong></li></ul><p><br></p><p>We focus initially on the Chinese economy and how UK investors could play the end of the Zero COVID-19 policy, should recent rumours prove to have any weight to them.</p><p><br></p><p><a href=\"https://ukinvestormagazine.co.uk/next-maintains-full-year-profit-guidance-despite-falling-sales/\" rel=\"noopener noreferrer\" target=\"_blank\">Next is a fantastic bellwether for the UK economy&nbsp;</a>and to see the retailer maintain their full year profit guidance, despite concerns around the health of the UK consumer.</p><p><br></p><p>GlaxoSmithKline sales have impressed the market with £7.8 billion sales in the third quarter, up 18% AER compared to the same period last year. We look deeper into the results and recent developments oil their pipeline of drugs.</p><p><br></p><p>We finish by looking at Sovereign Metal’s recent Titanium Rutile offtake agreement and ECR Minerals latest update.</p>","author_name":"UK Investor Magazine"}